Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)
10 Março 2023 - 1:23PM
Edgar (US Regulatory)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GSK plc
980 Great West Road
Brentford Middlesex
TW8 9GS T +44 (0)20 8047
5000 |
March 10, 2023
U.S. Securities
and Exchange Commission
100 F Street, N.E.
Washington, DC
20549
Ladies and Gentlemen,
Re: Notice of disclosure
filed in Securities Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as
amended, notice is hereby provided that GSK plc has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2022, which was filed with the Securities
and Exchange Commission on March 10, 2023. The disclosure can be found on page two of the Annual Report on Form 20-F, which incorporates by reference the information set forth under the heading
Section 13(r) of the US Exchange Act on page 305 of Exhibit 15.2 to the Annual Report on Form 20-F, and is incorporated by reference herein.
Respectfully submitted,
|
|
|
GSK plc |
|
|
By: |
|
/s/ Iain Mackay |
Name: |
|
Iain Mackay |
Title: |
|
Chief Financial Officer |
|
|
|
Registered in England & Wales Company
Number: 03888792 |
|
Registered Office: 980 Great West Road, Brentford, Middlesex, TW8 9GS |
GSK (PK) (USOTC:GLAXF)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
GSK (PK) (USOTC:GLAXF)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre GSK Plc (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Gsk Plc